Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLY-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Agonize TLR3 for Head and Neck Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR-3 for Gastrointestil Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TL-532 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YSHBV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Mar 22, 2021: AIM ImmunoTech announces addition of single-agent Ampligen arm to Cancer Center’s ongoing study in cancer patients with COVID-19
Mar 09, 2021: AIM ImmunoTech initiates dosing in intrasal Covid-19 drug study
Mar 02, 2021: Highlight & Pivotal start Phase IIa melanoma trial
Feb 24, 2021: AIM ImmunoTech’s subsidiary receives Orphan Medicil Product Desigtion by the European Medicines Agency for Ampligen to treat pancreatic cancer
Feb 17, 2021: AIM ImmunoTech to commence study of intrasal Covid-19 therapy
Feb 17, 2021: AIM ImmunoTech to commence study of intrasal Covid-19 therapy
Feb 10, 2021: AIM ImmunoTech announces the expansion of its pancreatic cancer program to include new patients in the Netherlands
Jan 29, 2021: AIM ImmunoTech enters into agreement for proposed intrasal safety study of ampligen
Jan 07, 2021: AIM doses first ?long hauler’ patient in trial of post-Covid-19 infection
Dec 24, 2020: AIM ImmunoTech announces availability of the ME/CFS clinical trial of its drug Ampligen for enrollment to COVID-19 ?Long Haulers’
Dec 23, 2020: Open Orphan: Successful completion of PrEP Biopharm Toxicology study for respiratory ’viral mimic’
Dec 21, 2020: AIM ImmunoTech’s drug Ampligen awarded FDA’s Orphan Drug Desigtion status for the treatment of pancreatic cancer
Dec 16, 2020: PrEP Biopharm announces successful completion of PrEP-001 toxicology study ebling phase 2b field study of PrEP-001 against all respiratory viruses
Nov 25, 2020: AIM announces milestone in covid-19 treatment and prevention efforts with first patient dosed in study evaluating Ampligen as part of combition treatment for patients with cancer and covid-19
Nov 02, 2020: AIM ImmunoTech announces PLOS ONE’s publication of new data alyses showing importance of disease duration on Ampligen’s positive role in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by 13therapeutics Inc, 2021
Pipeline by AIM ImmunoTech Inc, 2021
Pipeline by Glysantis Inc, 2021
Pipeline by HDT Bio Corp, 2021
Pipeline by Highlight Therapeutics SL, 2021
Pipeline by Oncovir Inc, 2021
Pipeline by PrEP Biopharm Ltd, 2021
Pipeline by Provention Bio Inc, 2021
Pipeline by Tollys SAS, 2021
Pipeline by Yisheng Biopharma Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021